DB05405InvestigationalProtein Based Therapies
XTL001 is an investigational monoclonal antibody (MAb) product developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in patients chronically infected with hepatitis B...
- Mechanism
- Curator reviewed
XTL001 is a combination of two high-affinity, fully human monoclonal antibodies that bind to distinct sites on the surface antigen of HBV to neutralize the virus and limit viral escape.
- Primary indication
- Investigated for use/treatment in hepatitis (viral, B).Curator reviewed
- Code names
- XTL-001
Resolves to
Compound
What you can answer from here — as of June 12, 2020
Which companies are running trials of XTL-001, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account